(Reuters) – Eli Lilly and Co said on Friday it had requested the U.S. Food and Drug Administration to revoke the emergency use authorization granted to its COVID-19 antibody bamlanivimab alone due to the full availability of its combination therapy.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Amy Caren Daniel)
